Full-Time

R&D Molecular Associate

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Mid, Senior

Chicago, IL, USA

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree with 2+ years experience in a molecular lab or completion of an advanced technical certificate program with a strong molecular lab component
  • Highly organized and systematic, superb attention to detail and ability to complete tasks with a high degree of accuracy
  • Proven ability to learn new skills quickly and adapt to new processes smoothly
  • Hands-on experience with any of the following molecular methods is highly desired: NGS library preparation methods, PCR methods such as: PCR, qPCR, RT-PCR, ddPCR, MLPA, Sanger Sequencing, Nucleic acid ligations, Nucleic acid analysis such as: quantitation by absorbance/fluorescence, gel & capillary electrophoresis, Magnetic bead-based DNA/RNA purification and size selection, DNA hybridization arrays
Responsibilities
  • Under the guidance of senior scientific staff, support the development of cutting-edge molecular assays for our high-throughput CAP/ CLIA/ NYSDOH accredited clinical lab
  • Assist in troubleshooting and quality control initiatives
  • Assist with development of automated processes
  • Execute molecular protocols with a high degree of precision and attention to detail
  • Generate detailed documentation of experimental execution
  • Process clinical samples through wet lab workflows

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data to assist physicians in making informed treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights, aiming to improve patient care and support drug development.

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

5%

1 year growth

14%

2 year growth

35%
Simplify Jobs

Simplify's Take

What believers are saying

  • Integration with Flatiron's OncoEMR enhances genomic data accessibility for oncologists.
  • Acquisition of Ambry Genetics expands Tempus's capabilities in medical diagnostics and testing.
  • Collaboration with BioNTech leverages real-world data for enhanced drug development.

What critics are saying

  • Ambry Genetics acquisition may strain financial resources and impact operational efficiency.
  • Collaboration with Flatiron Health may face data privacy and interoperability issues.
  • Immune Profile Score algorithmic test may encounter regulatory scrutiny, delaying adoption.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform aids drug development by discovering novel targets and evaluating treatments.
  • Tempus's pan-cancer organoid platform enhances personalized therapeutic opportunities for cancer patients.

Help us improve and share your feedback! Did you find this helpful?